Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
Hengmiao Cheng(Pfizer (United States)), Ru Zhou(University of British Columbia), Tod Smeal(Pfizer (United States)), Michelle Hemkens(Pfizer (United States)), Scott L. Weinrich(Pfizer (United States)), Sajiv K. Nair(Pfizer (United States)), Sangita M. Baxi(Pfizer (United States)), K.S. Gajiwala(Pfizer (United States)), Brion W. Murray(Pfizer (United States)), Martha A. Ornelas(Pfizer (United States)), Marlena Walls(Pfizer (United States)), Michael Zientek(Pfizer (United States)), Jun Feng(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Khanh Tran(Pfizer (United States)), Shuibo Xin(WuXi AppTec (China)), Shuiwang Wang(WuXi AppTec (China)), Chau Almaden(Pfizer (United States)), Hong Shen(University of Michigan), Susan E. Kephart(Pfizer (United States)), Deepak Dalvie(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Jean Matthews(Pfizer (United States)), Elaine Tseng(University of California, San Francisco), Mehran Jalaie(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Rose Ann Ferre(Pfizer (United States)), Amy Jackson-Fisher(Yale University), Simon Bailey(The University of Melbourne), Asako Nagata(Pfizer (United States)), Sujin Cho-Schultz(Pfizer (United States)), Suvi T. M. Orr(Tracon Pharmaceuticals (United States)), Jim Solowiej(Pfizer (United States)), Sherry Niessen(Pfizer (United States)), Beth Lunney(Pfizer (United States)), Doug Behenna(Pfizer (United States)), Ted O. Johnson(Pfizer (United States)), Mason Pairish(Pfizer (United States)), William F. Vernier(Pfizer (United States)), Kevin K.‐C. Liu(Pfizer (United States)), Zhengyu Liu(Sun Yat-sen University), Hai‐Wei Xu(WuXi AppTec (China)), Scott C. Sutton(Pfizer (United States)), Daniel Richter(Pfizer (United States)), Min-Jean Yin(Maxygen (United States)), Dac M. Dinh(Pfizer (United States)), Shijian Ren(WuXi AppTec (China)), Simon Planken(Pfizer (United States)), Jennifer Lafontaine(Pfizer (United States)), Kevin Ryan(Pfizer (United States))
Cited by 93
Related Papers
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382
Lipophilic Efficiency as an Important Metric in Drug Design
|Journal of Medicinal Chemistry|2018|340